Dosing and uses of Lanabiotic Ointment (neomycin/polymyxin B/ bacitracin/lidocaine)
Adult dosage forms and strengths
neomycin/polymyxin B/bacitracin/lidocaine
topical ointment
- (3.5mg/10,000units/500units/40mg)/g
Skin Infection Prevention
Apply small amount to cleansed wound 1-3 times/day; not to exceed 1 week
Pediatric dosage forms and strengths
neomycin/polymyxin B/bacitracin/lidocaine
topical ointment
- (3.5mg/10,000units/500units/40mg)/g
Skin Infection Prevention
Apply small amount to cleansed wound 1-3 times/day; not to exceed 1 week
Lanabiotic Ointment (neomycin/polymyxin B/ bacitracin/lidocaine) adverse (side) effects
Frequency not defined
Allergic contact dermatitis
Warnings
Contraindications
Hypersensitivity
Cautions
Ototoxicity and nephrotoxicity possible if treating large surface area or chronic use
Lidocaine may be significantly absorbed from mucosal surfaces and open wounds
Pregnancy and lactation
Pregnancy category: C
Lactation: unknown if neomycin, polymyxin B, or bacitracin excreted in breast milk; systemic absorption of topical lidocaine has been reported
Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Lanabiotic Ointment (neomycin/polymyxin B/ bacitracin/lidocaine)
Mechanism of action
Neomycin, polymyxin B, and bacitracin elicit bacteriostatic activity
Lidocaine provides local anesthetic effect
